Drug Shortage Report for BREVIBLOC PREMIXED INJECTION
Report ID | 101500 |
Drug Identification Number | 02309238 |
Brand name | BREVIBLOC PREMIXED INJECTION |
Common or Proper name | esmolol hydrochloride |
Company Name | BAXTER CORPORATION |
Market Status | MARKETED |
Active Ingredient(s) | ESMOLOL HYDROCHLORIDE |
Strength(s) | 10MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS |
Packaging size | 10 units/case (CA2J1415) |
ATC code | C07AB |
ATC description | BETA BLOCKING AGENTS |
Reason for shortage | Delay in shipping of the drug. |
Anticipated start date | 2019-12-17 |
Actual start date | 2019-12-17 |
Estimated end date | 2020-01-02 |
Actual end date | 2020-01-02 |
Shortage status | Resolved |
Updated date | 2020-01-03 |
Company comments | Baxter product BREVIBLOC Injection esmolol hydrochloride Solution, 10 mg/mL (100 mg/10 mL Vials) (DIN: 02188880) is available as an alternative if it aligns with clinical practice. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 7125 MISSISSAUGA ROAD MISSISSAUGA, ONTARIO CANADA L5N 0C2 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2019-12-17 | English | Compare |
v2 | 2019-12-17 | French | Compare |
v3 | 2019-12-18 | English | Compare |
v4 | 2020-01-03 | English | Compare |
v5 | 2020-01-03 | French | Compare |
Showing 1 to 5 of 5